{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:03:48Z","timestamp":1770073428455,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianostat alone and in combination with bortezomib in the treatment of multiple myeloma (MM), as well as preliminary first-in-human findings from an ongoing phase 1a study. Bisthianostat dose dependently induced acetylation of tubulin and H3 and increased PARP cleavage and apoptosis in RPMI-8226 cells. In RPMI-8226 and MM.1S cell xenograft mouse models, oral administration of bisthianostat (50, 75, 100\u2009mg\u00b7kg<jats:sup>-1<\/jats:sup>\u00b7d<jats:sup>-1<\/jats:sup>, bid) for 18 days dose dependently inhibited tumor growth. Furthermore, bisthianostat in combination with bortezomib displayed synergistic antitumor effect against RPMI-8226 and MM.1S cell in vitro and in vivo. Preclinical pharmacokinetic study showed bisthianostat was quickly absorbed with moderate oral bioavailability (<jats:italic>F<\/jats:italic>%\u2009=\u200916.9%\u201335.5%). Bisthianostat tended to distribute in blood with <jats:italic>V<\/jats:italic><jats:sub>ss<\/jats:sub> value of 0.31\u2009L\/kg. This distribution parameter might be beneficial to treat hematologic neoplasms such as MM with few side effects. In an ongoing phase 1a study, bisthianostat treatment was well tolerated and no grade 3\/4 nonhematological adverse events (AEs) had occurred together with good pharmacokinetics profiles in eight patients with relapsed or refractory MM (R\/R MM). The overall single-agent efficacy was modest, stable disease (SD) was identified in four (50%) patients at the end of first dosing cycle (day 28). These preliminary in-patient results suggest that bisthianostat is a promising HDACi drug with a comparable safety window in R\/R MM, supporting for its further phase 1b clinical trial in combination with traditional MM therapies.<\/jats:p>","DOI":"10.1038\/s41401-021-00728-y","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:04:43Z","timestamp":1627898683000},"page":"1091-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma"],"prefix":"10.1038","volume":"43","author":[{"given":"Yu-bo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-bei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-da","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-bo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa-jun","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6:a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"728_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"728_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811\u20139.","journal-title":"Br J Haematol"},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/2040620715592567","volume":"6","author":"A Sawas","year":"2015","unstructured":"Sawas A, Radeski D, O\u2019Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6:202\u20138.","journal-title":"Ther Adv Hematol"},{"key":"728_CR5","doi-asserted-by":"crossref","unstructured":"Chan TS, Tse E, Kwong YL. Chidamide in the treatment of peripheral T-cell lymphoma. OncoTargets Ther. 2017;10:347\u201352.","DOI":"10.2147\/OTT.S93528"},{"key":"728_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1358\/dot.2017.53.3.2595452","volume":"53","author":"Y Xu","year":"2017","unstructured":"Xu Y, Zhang P, Liu Y. Chidamide tablets: HDAC inhibition to treat lymphoma. Drugs Today. 2017;53:167\u201376.","journal-title":"Drugs Today"},{"key":"728_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu X, Ning Z, Li Z, Cao H, Wang X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable Rare Dis Res. 2016;5:185\u201391.","journal-title":"Intractable Rare Dis Res"},{"key":"728_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0776-0","volume":"11","author":"A Ganesan","year":"2019","unstructured":"Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics. 2019;11:174.","journal-title":"Clin Epigenetics"},{"key":"728_CR9","doi-asserted-by":"crossref","unstructured":"Panobinostat approved for multiple myeloma. Cancer Discov. 2015;5:OF4.","DOI":"10.1158\/2159-8290.CD-NB2015-040"},{"key":"728_CR10","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21:4767\u201373.","journal-title":"Clin Cancer Res"},{"key":"728_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/cancers11040475","volume":"11","author":"Y Imai","year":"2019","unstructured":"Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers. 2019;11:475.","journal-title":"Cancers"},{"key":"728_CR12","doi-asserted-by":"publisher","first-page":"e85061","DOI":"10.1172\/jci.insight.85061","volume":"1","author":"Y Imai","year":"2016","unstructured":"Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, et al. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight. 2016;1:e85061.","journal-title":"JCI Insight"},{"key":"728_CR13","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.18632\/oncotarget.26726","volume":"10","author":"M Iwasa","year":"2019","unstructured":"Iwasa M, Harada T, Oda A, Bat-Erdene A, Teramachi J, Tenshin H, et al. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-gamma. Oncotarget. 2019;10:1903\u201317.","journal-title":"Oncotarget"},{"key":"728_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/ml400470s","volume":"5","author":"F Chen","year":"2014","unstructured":"Chen F, Chai H, Su MB, Zhang YM, Li J, Xie X, et al. Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors. ACS Med Chem Lett. 2014;5:628\u201333.","journal-title":"ACS Med Chem Lett"},{"key":"728_CR15","first-page":"2191","volume":"55","author":"SD YU","year":"2020","unstructured":"Yu SD, Hou XY, Shen LJ, Zhang YM, Nan FJ, Wang Y, et al. Simultaneous determination of bisthianostat and its hydrolyzed N-hydroxyamide metabolite M351 in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS\/MS). Acta Pharm Sin. 2020;55:2191\u20137.","journal-title":"Acta Pharm Sin"},{"key":"728_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587\u2013600.","journal-title":"J Clin Oncol"},{"key":"728_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.2010.08126.x","volume":"149","author":"T Stuhmer","year":"2010","unstructured":"Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, et al. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol. 2010;149:529\u201336.","journal-title":"Br J Haematol"},{"key":"728_CR18","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"728_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","volume":"4","author":"BE Gryder","year":"2012","unstructured":"Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4:505\u201324.","journal-title":"Future Med Chem"},{"key":"728_CR20","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2006-04-016055","volume":"108","author":"L Catley","year":"2006","unstructured":"Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441\u20139.","journal-title":"Blood"},{"key":"728_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","volume":"33","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors. J Enzym Inhib Med Chem. 2018;33:714\u201321.","journal-title":"J Enzym Inhib Med Chem"},{"key":"728_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/187231207780363642","volume":"1","author":"P Sandhu","year":"2007","unstructured":"Sandhu P, Andrews PA, Baker MP, Koeplinger KA, Soli ED, Miller T, et al. Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. Drug Metab Lett. 2007;1:153\u201361.","journal-title":"Drug Metab Lett"},{"key":"728_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00280-007-0622-5","volume":"62","author":"KE Warren","year":"2008","unstructured":"Warren KE, McCully C, Dvinge H, Tjornelund J, Sehested M, Lichenstein HS, et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol. 2008;62:433\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"728_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/138920006774832578","volume":"7","author":"JH Lin","year":"2006","unstructured":"Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab. 2006;7:39\u201365.","journal-title":"Curr Drug Metab"},{"key":"728_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","volume":"18","author":"G Cengiz Seval","year":"2019","unstructured":"Cengiz Seval G, Beksac M. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma. Expert Opin Drug Saf. 2019;18:563\u201371.","journal-title":"Expert Opin Drug Saf"},{"key":"728_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1091581809352111","volume":"29","author":"JS Kerr","year":"2010","unstructured":"Kerr JS, Galloway S, Lagrutta A, Armstrong M, Miller T, Richon VM, et al. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol. 2010;29:3\u201319.","journal-title":"Int J Toxicol"},{"key":"728_CR27","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1021\/jm200388e","volume":"54","author":"MD Shultz","year":"2011","unstructured":"Shultz MD, Cao X, Chen CH, Cho YS, Davis NR, Eckman J, et al. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011;54:4752\u201372.","journal-title":"J Med Chem"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1021\/jm2003552","volume":"54","author":"H Wang","year":"2011","unstructured":"Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW, et al. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylami de (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem. 2011;54:4694\u2013720.","journal-title":"J Med Chem"},{"key":"728_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/bjc.2011.13","volume":"104","author":"AR Razak","year":"2011","unstructured":"Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 2011;104:756\u201362.","journal-title":"Br J Cancer"},{"key":"728_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/phar.1671","volume":"35","author":"S Afifi","year":"2015","unstructured":"Afifi S, Michael A, Azimi M, Rodriguez M, Lendvai N, Landgren O. Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: a focus on vorinostat and panobinostat. Pharmacotherapy. 2015;35:1173\u201388.","journal-title":"Pharmacotherapy"},{"key":"728_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00228-015-1967-z","volume":"72","author":"S Mu","year":"2016","unstructured":"Mu S, Kuroda Y, Shibayama H, Hino M, Tajima T, Corrado C, et al. Panobinostat PK\/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory multiple myeloma. Eur J Clin Pharmacol. 2016;72:153\u201361.","journal-title":"Eur J Clin Pharm"},{"key":"728_CR32","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals. 2010;3:2751\u201367.","journal-title":"Pharmaceuticals"},{"key":"728_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijcard.2016.06.012","volume":"219","author":"GG Schiattarella","year":"2016","unstructured":"Schiattarella GG, Sannino A, Toscano E, Cattaneo F, Trimarco B, Esposito G, et al. Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: systematic review of 62 studies and new hypotheses for future research. Int J Cardiol. 2016;219:396\u2013403.","journal-title":"Int J Cardiol"},{"key":"728_CR34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","volume":"53","author":"JL Wolf","year":"2012","unstructured":"Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma. Leuk Lymphoma. 2012;53:1820\u20133.","journal-title":"Leuk Lymphoma"},{"key":"728_CR35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190701817258","volume":"49","author":"P Richardson","year":"2008","unstructured":"Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502\u20137.","journal-title":"Leuk Lymphoma"},{"key":"728_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/cncr.25584","volume":"117","author":"R Niesvizky","year":"2011","unstructured":"Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117:336\u201342.","journal-title":"Cancer"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00728-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00728-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00728-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:47:09Z","timestamp":1648820829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00728-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00728-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}